Paper35484110
SARS-CoV-2 Omicron variant: recent progress and future perspectives.
Fan Y and 5 others. Signal Transduct Target Ther, 2022. Cited by 454 papers, by iCite.
Cite this record
ConductScience Library. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Papers, record 35484110. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35484110
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| SARS-CoV-2 | Major topic |
| Humans | |
| Immunization, Passive | |
| COVID-19 Serotherapy |
Source PubMed
References126
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34916215 | Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show. | BMJ | 2021 | https://conductscience.org/library/papers/34916215 | PubMed |
| 2 | 35086614 | Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. | Euro Surveill | 2022 | https://conductscience.org/library/papers/35086614 | PubMed |
| 3 | 32075877 | Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. | Science | 2020 | https://conductscience.org/library/papers/32075877 | PubMed |
| 4 | 35074136 | Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. | Lancet | 2022 | https://conductscience.org/library/papers/35074136 | PubMed |
| 5 | 34921135 | SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. | Signal Transduct Target Ther | 2021 | https://conductscience.org/library/papers/34921135 | PubMed |
| 6 | 33158808 | Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. | EBioMedicine | 2020 | https://conductscience.org/library/papers/33158808 | PubMed |
| 7 | 35046572 | mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. | Nat Med | 2022 | https://conductscience.org/library/papers/35046572 | PubMed |
| 8 | 35411997 | Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. | Trop Med Int Health | 2022 | https://conductscience.org/library/papers/35411997 | PubMed |
| 9 | 33743213 | Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. | Cell | 2021 | https://conductscience.org/library/papers/33743213 | PubMed |
| 10 | 32264791 | Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. | Circ Res | 2020 | https://conductscience.org/library/papers/32264791 | PubMed |
| 11 | 35034583 | Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. | Emerg Microbes Infect | 2022 | https://conductscience.org/library/papers/35034583 | PubMed |
| 12 | 35060999 | Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. | JAMA | 2022 | https://conductscience.org/library/papers/35060999 | PubMed |
| 13 | 35139269 | Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35139269 | PubMed |
| 14 | 35026151 | The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. | Cell | 2022 | https://conductscience.org/library/papers/35026151 | PubMed |
| 15 | 35140198 | ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/35140198 | PubMed |
| 16 | 35149106 | SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. | Environ Res | 2022 | https://conductscience.org/library/papers/35149106 | PubMed |
| 17 | 35081300 | Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35081300 | PubMed |
| 18 | 32422645 | Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. | Nature | 2020 | https://conductscience.org/library/papers/32422645 | PubMed |
| 19 | 34075212 | SARS-CoV-2 variants, spike mutations and immune escape. | Nat Rev Microbiol | 2021 | https://conductscience.org/library/papers/34075212 | PubMed |
| 20 | 34915551 | Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. | Clin Infect Dis | 2022 | https://conductscience.org/library/papers/34915551 | PubMed |
Cited by341
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 454 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42707259 | A viral-vectored multipathogen vaccine platform based on replication-competent vaccinia virus and adeno-associated virus. | Front Immunol | 2026 | https://conductscience.org/library/papers/42707259 | PubMed |
| 42549192 | Impact of SARS-CoV-2 Omicron infection on late pregnancy: an analysis of clinical characteristics, pathology of placenta and outcomes in a case-control study. | Open Med (Wars) | 2026 | https://conductscience.org/library/papers/42549192 | PubMed |
| 42419249 | Biochemical rationale for dietary management of COVID-19 patients: Indian traditional millets as a promising integrative nutritional strategy. | J Ayurveda Integr Med | 2026 | https://conductscience.org/library/papers/42419249 | PubMed |
| 42389543 | Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants. | Front Immunol | 2026 | https://conductscience.org/library/papers/42389543 | PubMed |
| 42334739 | Genomic surveillance of SARS-CoV-2: a resource-efficient wastewater-based workflow. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42334739 | PubMed |
| 42318393 | COVID-19 vaccination in pregnancy: efficacy of second-generation vaccines, maternal-neonatal safety, and strategies to address vaccine hesitancy. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42318393 | PubMed |
| 42316787 | The pivotal role of β-lactone stereochemistry in the development of SARS-CoV-2 Mpro inhibitors. | Protein Sci | 2026 | https://conductscience.org/library/papers/42316787 | PubMed |
| 42291020 | Nirmatrelvir/Ritonavir Efficacy in Immunocompetent Patients with Confirmed Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2: An Updated Systematic Review and Meta-analysis. | J Res Pharm Pract | 2026 | https://conductscience.org/library/papers/42291020 | PubMed |
| 42192199 | Monitoring viral evolution and epidemiological characteristics of SARS-CoV-2 during 2022-2023 using Integrated Genomic Surveillance. | Commun Med (Lond) | 2026 | https://conductscience.org/library/papers/42192199 | PubMed |
| 42116071 | An intramuscular prime-intranasal boost strategy for mRNA-LNP vaccine induces mucosal immune response against SARS-CoV-2 in murine model. | J Transl Med | 2026 | https://conductscience.org/library/papers/42116071 | PubMed |
| 42102110 | Socioeconomic inequalities and the COVID-19 pandemic in France: Territorial analyzes based on epidemic wave and metropolitan area. | PLoS One | 2026 | https://conductscience.org/library/papers/42102110 | PubMed |
| 42094075 | Epidemiological Trends of COVID-19 Infection and Symptom Incidence in China Following the Adjustment of Zero-COVID Policy: A Prospective, Community-Based Cohort Study. | Transbound Emerg Dis | 2026 | https://conductscience.org/library/papers/42094075 | PubMed |
| 42079734 | Genomic insights into SARS-CoV-2 evolution in Yantai, China after the adjustment of the dynamic zero-COVID policy in 2023. | PeerJ | 2026 | https://conductscience.org/library/papers/42079734 | PubMed |
| 42028070 | Neurocognitive and Psychiatric Outcomes Following Mild to Moderate COVID-19: A Longitudinal Comparison of Alpha/Delta and Omicron Variants. | Neuropsychiatr Dis Treat | 2026 | https://conductscience.org/library/papers/42028070 | PubMed |
| 41973264 | Viral genotype and the pace of epidemic waves: an assessment from SARS-CoV 2 genomics and wastewater surveillance data. | Arch Virol | 2026 | https://conductscience.org/library/papers/41973264 | PubMed |
| 41950377 | Cardiovascular and mortality risks following COVID-19-related versus non-COVID-19-related chronic obstructive pulmonary disease exacerbations. | Ann Am Thorac Soc | 2026 | https://conductscience.org/library/papers/41950377 | PubMed |
| 41922730 | Two years of SARS-CoV-2 genomic surveillance capacity development in Guinea. | Sci Rep | 2026 | https://conductscience.org/library/papers/41922730 | PubMed |
| 41826917 | Critical care trends across five waves of COVID-19 in Pakistan: A multi-center observational study from the Pakistan Registry of Intensive CarE (PRICE). | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/41826917 | PubMed |
| 41816409 | A narrative review of SARS-CoV-2 variants and long COVID. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/41816409 | PubMed |
| 41710745 | Characterization of the Cross-Resistance of SARS-CoV‑2 Main Protease Inhibitors, Ibuzatrelvir, Ensitrelvir, and Nirmatrelvir. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/41710745 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACE2 | 59272 | PubTator's text mining | https://conductscience.org/library/genes/59272 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| CTSL | 1514 | PubTator's text mining | https://conductscience.org/library/genes/1514 | NCBI Gene |
| FURIN | 5045 | PubTator's text mining | https://conductscience.org/library/genes/5045 | NCBI Gene |
| IFNA1 | 3439 | PubTator's text mining | https://conductscience.org/library/genes/3439 | NCBI Gene |
| MAVS | 57506 | PubTator's text mining | https://conductscience.org/library/genes/57506 | NCBI Gene |
| NFKB1 | 4790 | PubTator's text mining | https://conductscience.org/library/genes/4790 | NCBI Gene |
| TMPRSS2 | 7113 | PubTator's text mining | https://conductscience.org/library/genes/7113 | NCBI Gene |
| VTN | 7448 | PubTator's text mining | https://conductscience.org/library/genes/7448 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35484110
GET https://conductscience.org/api/papers/v1/35484110/references?page=2